Navigation Links
Has the 'Golden Age' of global health funding come to an end?
Date:2/6/2013

WASHINGTON, DC Despite dire predictions in the wake of the economic crisis, donations to health projects in developing countries appear to be holding steady, according to new research from the Institute for Health Metrics and Evaluation (IHME) at the University of Washington.

After reaching a historic high of $28.2 billion in 2010, development assistance for health dropped in 2011 and recovered in 2012. The strong growth in spending from the GAVI Alliance and UNICEF counterbalanced declines in health spending among other donors.

The new findings are being announced today at the Center for Global Development and published online as part of the fourth annual edition of IHME's financing series, Financing Global Health 2012: The End of the Golden Age?

This report tracks development assistance for health from government aid agencies, multilateral donors, and private foundations and charities. It explores funding trends over three periods: the "moderate-growth" period from 1990 to 2001, the "rapid-growth" period from 2001 to 2010, and the "no-growth" period from 2010 to 2012.

Financing Global Health 2012 also analyzes health spending from governments in developing countries between 1990 and 2010. For those interested in using the global health financing datasets compiled as part of this research, IHME provides detailed results data and the statistical code used to generate these results for download on its website.

"There were predictions that the sky was going to fall on global health funding, but that didn't happen," said IHME Director and report co-author Dr. Christopher Murray. "Only time can tell whether the stagnation will continue, but the global health community needs to be prepared either way."

Priority setting has become even more important as global health funding has flatlined. Many donors have been forced to re-evaluate funding decisions to adapt to a new global health landscape. From 2011 to 2012, overall health spending channeled through government aid agencies dropped by 4.4%. Development assistance for health from the US, the largest donor, dropped by 3.3%, and health funding from France and Germany declined by 13% and 9.1%, respectively.

Among the six largest bilateral donors, only donations from the UK and Australia increased from 2011 to 2012.

By combining health funding estimates with the results of the newly published Global Burden of Disease (GBD) Study 2010, the report provides metrics that can help inform donor priority setting. GBD 2010 quantified premature death and disability, or disease burden, from 291 different diseases and injuries worldwide. Comparisons between the amount of development assistance for health that a country receives and its disease burden provide useful tools for assessing need versus funding.

"This analysis highlights the mismatch between donor priorities and global health needs," said Amanda Glassman, Director of Global Health Policy and a senior fellow at the Center for Global Development. "Before you can make a decision on where to allocate resources, you must first understand where that money is most needed."

Many developing countries with the highest disease burdens did not receive the most health funding. When comparing disease-specific funding and disease burden, such as malaria assistance versus burden of malaria, it becomes clear that certain countries receive much less funding than one might expect. For example, the low-income countries Burundi, Guinea, Mali, and Niger were among the top 20 countries in terms of malaria burden, but were not among the top 20 recipients of malaria funding.

"For some diseases, there is a clear disconnect between funding and burden measured by both mortality and disability," explains IHME Assistant Professor Michael Hanlon. "These comparisons serve as a guide for policymakers to discuss, reassess, and improve upon their health spending."

Other major findings from the report include:

  • GAVI continued to have very strong rates of growth. In 2012, expenditure by GAVI reached an estimated $1.76 billion in 2012, a 41.9% increase over 2011.

  • The sub-Saharan African region received the largest share of health funding. In 2010 (the most recent year for which recipient-level estimates are available), sub-Saharan Africa's share was $8.1 billion, or 28.7% of total health funding.

  • Health funding for HIV/AIDS, tuberculosis, and maternal, newborn, and child health continued to grow through 2010. DAH for health sector support, non-communicable diseases, and malaria fell slightly from 2009 to 2010.

  • Even at the peak of health funding from donors in 2010, the spending by governments on health in their own countries was $521 billion, more than 18 times higher than total donor funding in the same year. That country spending grew 6% from 2009 to 2010.

"Fluctuation in funding and the variance in global burden of disease highlight the need for policymakers to stay informed with the most accurate information available on the evolving global health landscape," Murray said.


'/>"/>

Contact: Rhonda Stewart
stewartr@uw.edu
206-861-6684
Institute for Health Metrics and Evaluation
Source:Eurekalert

Related medicine news :

1. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
2. Golden age of prostate cancer treatment hailed as fourth drug in 2 years extends life
3. Celebrating the golden anniversary of a remarkable science agency
4. Eight scientists honored in first annual Golden Goose Awards
5. LA BioMed investigator, Dr. Rodney White, receives the 2012 Golden Goose Award
6. Three Penn State research pioneers among first Golden Goose honorees
7. NIH awards $20 million over 5 years to train next generation of global health researchers
8. Canada should play a role in addressing the global cancer epidemic
9. Global cardiology leaders meet in Dubai
10. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
11. International breast health global summit will focus on supportive care and quality of life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... with the Home Care Association of America (HCAOA). This agreement allows HCAOA members ... services, as well as discounts on Accreditation University (AU) educational resources that help ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... to announce the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to ... since it streamlines the reporting process and provides a familiar interface that does ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... ... April 28, 2017 , ... GlycoMark, Inc. announced today ... throughout the Northeast U.S. , GlycoMark is the only clinically available blood ... provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America ... lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start ... ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving labor ...
Breaking Medicine News(10 mins):
(Date:4/24/2017)... 2017 Solentim, the developer of instrumentation ... of a major new product line called the ... VIPS has been developed for automatically seeding single ... part of the process to generate clonally-derived cell ... more reliable solution when compared to traditional single ...
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... April 20, 2017  AbbVie (NYSE: ABBV), a ... (n=145/146) of chronic hepatitis C virus (HCV) infected ... 6 and compensated cirrhosis (Child-Pugh A) achieved sustained ... ) with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir ... seen following 12 weeks of G/P treatment without ...
Breaking Medicine Technology: